124584-08-3

Basic information

• Product Name: BNP-32 (HUMAN)
• Synonyms: Nesiritide [USAN:INN];H-SER-PRO-LYS-MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY-ARG-LYS-MET-ASP-ARG-ILE-SER-SER-SER-SER-GLY-LEU-GLY-CYS-LYS-VAL-LEU-ARG-ARG-HIS-OH;H-SER-PRO-LYS-MET-VAL-GLN-GLY-SER-GLY-CYS-PHE-GLY-ARG-LYS-MET-ASP-ARG-ILE-SER-SER-SER-SER-GLY-LEU-GLY-CYS-LYS-VAL-LEU-ARG-ARG-HIS-OH (DISULFIDE BRIDGE: 10-26);BRAIN NATRIURETIC PEPTIDE (1-32), HUMAN;BRAIN(B-TYPE) NATRIURETIC PEPTIDE-32 (HUMAN);BRAIN NATRIURETIC PEPTIDE, HUMAN;BRAIN NATRIURETIC PEPTIDE-32 (HUMAN);B-TYPE (BRAIN) NATRIURETIC PEPTIDE-32 (HUMAN)
• CAS NO: 124584-08-3
• Molecular Formula: C143H244N50O42S4
• Molecular Weight: 3464.04
• EINECS: 1312995-182-4
• Mol File: 124584-08-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /powder
• Density: 1.529 g/cm³
• Storage Temp.: −20°C
• Water Solubility: Soluble in water at 1mg/ml
• CAS DataBase Reference: BNP-32 (HUMAN)(CAS DataBase Reference)
• NIST Chemistry Reference: BNP-32 (HUMAN)(124584-08-3)
• EPA Substance Registry System: BNP-32 (HUMAN)(124584-08-3)

Safety Data

• WGK Germany: 3
• RTECS: EE1534000
• Hazardous Substances Data: 124584-08-3(Hazardous Substances Data)

Usage

Description

BNP-32 (Human), also known as brain natriuretic peptide, is a naturally occurring 32 amino acid peptide with a disulfide-bonded 17 amino acid ring structure. It is mainly produced in myoendocrine cells of the heart ventricles and plays a crucial role in blood pressure control and cardiovascular homeostasis. The gene encoding BNP-32 is localized on human chromosome 1p36.22 and is implicated in several biological functions such as diuresis, natriuresis, hypotensive action, and inhibition of aldosterone secretion. BNP-32 acts as a potential biomarker of high left ventricular-diastolic pressure in patients with symptomatic left ventricular (LV) dysfunction, and its elevated expression is observed in acute myocardial infarction (AMI) patients.

Uses

Used in Pharmaceutical Industry:
BNP-32 (Human) is used as a therapeutic agent for the treatment of congestive heart failure. It is administered as a human recombinant form, such as Nesiritide, which is the first intravenous treatment for patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity. Nesiritide binds to the A-type natriuretic peptide receptor on the surface of endothelial and smooth muscle cells, stimulating the production of the second messenger cGMP, which mediates predominantly vascular smooth muscle cell relaxation. It also facilitates the elimination of sodium and water by the kidney and decreases the secretion of certain hormones, such as adrenalin, angiotensin II, aldosterone, and endothelin, which provoke long-term detrimental effects, including blood vessel constriction and blood pressure elevation.
Used in Clinical Trials:
BNP-32 (Human) is used as a biomarker for assessing left ventricular-diastolic pressure in patients with symptomatic left ventricular (LV) dysfunction. Its elevated expression in acute myocardial infarction (AMI) patients helps in monitoring and managing the condition.
Used in Diagnostic Industry:
BNP-32 (Human) is used as a diagnostic tool to detect and monitor heart failure and left ventricular dysfunction in patients. Its measurement in blood samples can provide valuable information on the severity and progression of the disease, aiding in the development of appropriate treatment plans.
Brand Name:
Natrecor (Biochemie, Austria)

Originator

Scios (US)

Biochem/physiol Actions

Brain natriuretic peptide (type B natriuretic peptide) was originally isolated from brain, but is mainly produced in myoendocrine cells of the heart ventricles from which it is released into the circulation. It is involved in blood pressure control and cardiovascular homeostasis.